BioSpace13h
PTC Scraps ALS Asset Utreloxastat After Mid-Stage Fail, Analysts Look to PKU Opportunity
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...
BioSpace13h
Trump Picks Stanford’s Jay Bhattacharya as NIH Lead
Trump is rounding out his health cabinet with another controversial figure: one of the authors of the Great Barrington ...
BioSpace3h
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
BioSpace23h
Roche Buys Poseida for up to $1.5B, Leaning Into Off-the-Shelf CAR T
The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...
BioSpace22h
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...
BioSpace22h
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...